Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiff Oncology, Inc. filings document regulatory disclosures for a clinical-stage oncology company developing onvansertib and PLK1-inhibition programs. Recent Form 8-K reports cover financial results, business updates, Regulation FD presentation materials, CRDF-004 clinical disclosures in first-line RAS-mutated metastatic colorectal cancer and other material events tied to the company's development strategy.
The company's proxy and current reports also address board and executive governance, officer appointments and departures, separation agreements, compensation arrangements, equity awards and Nasdaq inducement grants. These filings include formal disclosure of risk themes common to clinical-stage biotechnology issuers, including clinical-trial uncertainty, financing needs, dependence on key personnel and operating disruptions.
Cardiff Oncology, Inc. Chief Financial Officer Joshua B. Muntner reported a compensation-related grant of 486,650 stock options on April 6, 2026. These options allow him to purchase common stock at an exercise price of $1.58 per share and expire on April 6, 2036.
According to the vesting terms, 121,663 options vest on April 6, 2027, and 10,139 options vest monthly for 36 months thereafter. Following the grant, he holds 487,150 stock options and 500 shares of common stock, all reported as directly owned.
Cardiff Oncology is reshaping its leadership team, naming board member and Interim CEO Mani Mohindru, Ph.D., as President and Chief Executive Officer. She receives a base salary of $655,000, a $100,000 bonus and a 55% annual discretionary bonus, plus incentive stock options totaling 800,000 shares with exercise prices of $1.56 and $1.62 per share, vesting over four years.
The company appointed Josh Muntner as Chief Financial Officer effective April 6, 2026, with a $475,000 base salary, 40% annual discretionary bonus and a non-qualified inducement option to purchase 486,650 shares at $1.58 per share, vesting over four years. Ajay Aggarwal, MD, MBA, will become Chief Operating Officer on April 27, 2026, with a $490,000 base salary, 40% annual discretionary bonus and an expected grant of 400,000 stock options.
Cardiff Oncology highlights that there are no special arrangements or family relationships involved in these appointments. The company continues to advance its lead PLK1 inhibitor, onvansertib, in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer and other PLK1-driven tumors.
Cardiff Oncology, Inc. reported that Chief Executive Officer Mani Mohindru received a grant of stock options covering 600,000 shares of common stock. These options have an exercise price of $1.62 per share and expire on March 31, 2036.
The grant is compensation-related, not an open-market trade. Following this award, the filing shows option holdings of 968,766 stock options. A footnote states that 150,000 options vest on March 31, 2027, with 12,500 options vesting monthly for 36 months thereafter, creating a multi-year vesting schedule.
Cardiff Oncology, Inc. entered into separation agreements on March 27, 2026 with former CEO Dr. Mark Erlander and former CFO James Levine, who had previously stepped down as part of a strategic review.
Dr. Erlander will receive his $635,000 base salary paid over 12 months from the separation date, his 2025 bonus of $122,238, 50% of his 2026 target bonus prorated over 12 months, and up to 12 months of continued healthcare benefits. He also signed a consulting agreement, and his stock options will continue to vest until June 2026, after which vested options are exercisable for 12 months.
Mr. Levine will receive his $490,000 base salary paid over 12 months, his 2025 bonus of $61,740, 50% of his 2026 target bonus prorated over 12 months, and up to 12 months of continued healthcare benefits. His vested stock options are exercisable for 12 months after the separation date. Both executives agreed to a general release and confidentiality, and on March 27, 2026, Dr. Erlander also resigned as a director.
Cardiff Oncology Inc: Ownership update by The Vanguard Group. The filing amends a Schedule 13G to report 0 shares beneficially owned, representing 0% of Common Stock as of the report. The filing notes an internal realignment at The Vanguard Group, Inc. effective January 12, 2026, with certain subsidiaries now reporting separately.
Cardiff Oncology furnished a corporate presentation highlighting new Phase 2 data for its oral PLK1 inhibitor onvansertib in first-line RAS‑mutated metastatic colorectal cancer. In the CRDF‑004 trial, onvansertib 30 mg plus FOLFIRI/bevacizumab showed a confirmed objective response rate of 72.2% versus 43.2% for standard chemotherapy regimens and a progression‑free survival hazard ratio of 0.38 versus FOLFIRI/bevacizumab, with median progression‑free survival not yet reached in the onvansertib arms at the January 22, 2026 cut. Safety data indicate no significant added toxicity, supporting selection of the 30 mg dose with FOLFIRI/bevacizumab for a planned registrational program. The company plans an FDA meeting in the first half of 2026 and aims to initiate a Phase 3 trial in the second half of 2026, and reports $58.3 million in cash, cash equivalents, and short‑term investments, funding operations into the first quarter of 2027.
Cardiff Oncology reported full-year 2025 results and highlighted strong Phase 2 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer. In the CRDF-004 trial, the 30 mg onvansertib + FOLFIRI/bevacizumab arm achieved a confirmed objective response rate of 72.2%, versus 43.2% across combined standard-of-care arms, and showed significantly longer progression-free survival (hazard ratio 0.37, p<0.05).
The company plans to advance the 30 mg dose with FOLFIRI/bevacizumab into a planned registrational program, with detailed data and registrational plans expected in the first half of 2026 after FDA discussions. Leadership was realigned for late-stage development, including appointing Mani Mohindru as interim CEO.
Financially, 2025 royalty revenue was $593,000 and total operating expenses were $49.6 million. Net loss attributable to common stockholders was $45.9 million, or $0.69 per share, with weighted-average shares outstanding of 66.8 million. Cash, cash equivalents and short-term investments totaled $58.3 million as of December 31, 2025, which the company believes will fund operations into the first quarter of 2027.
Cardiff Oncology files its annual report describing a clinical‑stage pipeline centered on onvansertib, an oral, highly selective PLK1 inhibitor being tested across multiple cancers, led by a Phase 2 trial in first‑line RAS‑mutated metastatic colorectal cancer in partnership with Pfizer Ignite.
Updated CRDF‑004 data show a confirmed objective response rate of 72.2% for the 30 mg onvansertib plus FOLFIRI/bevacizumab arm versus 43.2% for standard of care, with a progression‑free survival hazard ratio of 0.37 versus standard of care and a generally well‑tolerated safety profile.
The company remains loss‑making, with a 2025 net loss of about $45.9 million, an accumulated deficit of roughly $430.0 million, cash and investments of $58.3 million, and substantial doubt about its ability to continue as a going concern, implying a need for additional capital. Cardiff also discloses a February 2026 notice from Nerviano alleging material breach of the onvansertib license; Cardiff disputes the claims but notes that an adverse outcome could jeopardize key intellectual property rights and materially harm its business.
Cardiff Oncology, Inc. reported that Chief Accounting Officer Lindsay Brigitte Ute acquired a grant of 200,000 stock options on February 13, 2026. The options were granted at an exercise price of $0.00 per share, reflecting a cost-free award rather than an open-market purchase.
Following this transaction, Ute held a total of 1,025,334 stock options directly. According to the vesting terms, 50,000 options vest on February 13, 2027, and 4,166 options vest monthly for the subsequent 36 months, spreading the remainder of the award over three years.
Mohindru Mani reported acquisition or exercise transactions in this Form 4 filing.
Cardiff Oncology, Inc. reported that Interim CEO and director Mani Mohindru received a grant of stock options. The award covers 200,000 stock options, recorded at a price of $0.0000 per option, and increases her directly held option position to 368,766 options following the transaction.